Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Pharmacological modulation of cell death in atherosclerosis: a promising approach towards plaque stabilization?

Martinet W, Schrijvers DM, De Meyer GR.

Br J Pharmacol. 2011 Sep;164(1):1-13. doi: 10.1111/j.1476-5381.2011.01342.x. Review.

2.

Selective depletion of macrophages in atherosclerotic plaques via macrophage-specific initiation of cell death.

Martinet W, Verheye S, De Meyer GR.

Trends Cardiovasc Med. 2007 Feb;17(2):69-75. Review.

PMID:
17292050
3.

Sudden coronary death caused by pathologic intimal thickening without atheromatous plaque formation.

Tavora F, Cresswell N, Li L, Ripple M, Fowler D, Burke A.

Cardiovasc Pathol. 2011 Jan-Feb;20(1):51-7. doi: 10.1016/j.carpath.2009.08.004. Epub 2009 Nov 12.

PMID:
19913444
4.
5.

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.

Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT.

Circulation. 2003 Oct 14;108(15):1772-8. Review.

6.

Vulnerable plaque and inflammation: potential clinical strategies.

Drakopoulou M, Toutouzas K, Michelongona A, Tousoulis D, Stefanadis C.

Curr Pharm Des. 2011 Dec;17(37):4190-209. Review.

PMID:
22204378
7.

Autophagy in atherosclerosis: a potential drug target for plaque stabilization.

Schrijvers DM, De Meyer GR, Martinet W.

Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2787-91. doi: 10.1161/ATVBAHA.111.224899. Review.

8.

Molecular and cellular targets of the MRI contrast agent P947 for atherosclerosis imaging.

Ouimet T, Lancelot E, Hyafil F, Rienzo M, Deux F, Lemaître M, Duquesnoy S, Garot J, Roques BP, Michel JB, Corot C, Ballet S.

Mol Pharm. 2012 Apr 2;9(4):850-61. doi: 10.1021/mp2003863. Epub 2012 Mar 8.

PMID:
22352457
9.

Heme oxygenase-1 inhibits progression and destabilization of vulnerable plaques in a rabbit model of atherosclerosis.

Li T, Tian H, Zhao Y, An F, Zhang L, Zhang J, Peng J, Zhang Y, Guo Y.

Eur J Pharmacol. 2011 Dec 15;672(1-3):143-52. doi: 10.1016/j.ejphar.2011.09.188. Epub 2011 Oct 10.

PMID:
22004613
10.

How do we prevent the vulnerable atherosclerotic plaque from rupturing? Insights from in vivo assessments of plaque, vascular remodeling, and local endothelial shear stress.

Andreou I, Antoniadis AP, Shishido K, Papafaklis MI, Koskinas KC, Chatzizisis YS, Coskun AU, Edelman ER, Feldman CL, Stone PH.

J Cardiovasc Pharmacol Ther. 2015 May;20(3):261-75. doi: 10.1177/1074248414555005. Epub 2014 Oct 21. Review.

PMID:
25336461
11.

Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies.

Silvestre-Roig C, de Winther MP, Weber C, Daemen MJ, Lutgens E, Soehnlein O.

Circ Res. 2014 Jan 3;114(1):214-26. doi: 10.1161/CIRCRESAHA.114.302355. Review.

12.

Autophagy in atherosclerosis: a cell survival and death phenomenon with therapeutic potential.

Martinet W, De Meyer GR.

Circ Res. 2009 Feb 13;104(3):304-17. doi: 10.1161/CIRCRESAHA.108.188318. Review.

13.

From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report.

Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, Fayad Z, Budoff MJ, Rumberger J, Naqvi TZ, Shaw LJ, Faergeman O, Cohn J, Bahr R, Koenig W, Demirovic J, Arking D, Herrera VL, Badimon J, Goldstein JA, Rudy Y, Airaksinen J, Schwartz RS, Riley WA, Mendes RA, Douglas P, Shah PK; SHAPE Task Force.

Am J Cardiol. 2006 Jul 17;98(2A):2H-15H. Epub 2006 Jun 12. Review.

PMID:
16843744
14.

Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events.

Peeters W, de Kleijn DP, Vink A, van de Weg S, Schoneveld AH, Sze SK, van der Spek PJ, de Vries JP, Moll FL, Pasterkamp G.

Eur Heart J. 2011 Jul;32(14):1758-68. doi: 10.1093/eurheartj/ehq387. Epub 2010 Nov 8.

15.

[The progress of nuclear medicine and magnetic resonance molecular imaging of atherosclerotic vulnerable plaques].

Zhao ZM, Qin SC.

Sheng Li Ke Xue Jin Zhan. 2011 Apr;42(2):86-90. Review. Chinese.

PMID:
21770253
16.

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.

Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT.

Circulation. 2003 Oct 7;108(14):1664-72. Review.

17.

Plaque in superficial femoral arteries indicates generalized atherosclerosis and vulnerability to coronary death: an autopsy study.

Dalager S, Falk E, Kristensen IB, Paaske WP.

J Vasc Surg. 2008 Feb;47(2):296-302. doi: 10.1016/j.jvs.2007.10.037.

18.

Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability.

Erbel C, Dengler TJ, Wangler S, Lasitschka F, Bea F, Wambsganss N, Hakimi M, Böckler D, Katus HA, Gleissner CA.

Basic Res Cardiol. 2011 Jan;106(1):125-34. doi: 10.1007/s00395-010-0135-y. Epub 2010 Dec 1.

PMID:
21116822
19.

Simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p(53), Bcl-2 and Bcl-xL.

Qin W, Lu Y, Zhan C, Shen T, Dou L, Man Y, Wang S, Xiao C, Bian Y, Li J.

Cardiovasc Drugs Ther. 2012 Feb;26(1):23-30. doi: 10.1007/s10557-011-6347-z.

PMID:
22038096
20.

Sizing up stability: combination therapy with Apo-AI peptide mimetics and statins in systemic lupus erythematosus-mediated atherosclerosis.

Mendez-Fernandez Y, Major A.

Arthritis Res Ther. 2010;12(5):139. doi: 10.1186/ar3115. Epub 2010 Sep 15.

Items per page

Supplemental Content

Write to the Help Desk